Modular Medical Files New $150M Universal Shelf, Establishes $100M At-The-Market Offering Program Amidst Liquidity Crisis

summarizeSummary

Modular Medical, Inc. has filed an S-3 shelf registration for up to $150 million in securities, including a $100 million At-The-Market (ATM) offering program, to address its immediate liquidity needs and going concern doubts, following recent FDA approval and Nasdaq compliance.

check_boxKey Events · Financing and Capital Events · MODD

• New Universal Shelf Registration Filed

  Modular Medical, Inc. has filed a new S-3 universal shelf registration statement, allowing it to offer and sell up to $150,000,000 in common stock, preferred stock, debt securities, warrants, and units from time to time.

• Establishes $100M At-The-Market (ATM) Program

  As part of the shelf registration, the company has established a new At-The-Market (ATM) offering program with Maxim Group LLC, enabling it to sell up to $100,000,000 of common stock into the market.

• Addresses Immediate Liquidity Crisis

  This capital raise capacity is a direct response to the company's previously disclosed immediate liquidity crisis and substantial doubt about its ability to continue as a going concern, making it a critical step for operational continuity.

• Potential for Significant Dilution

  The potential offering size, particularly the $100 million ATM program, represents a substantial multiple of the company's current market capitalization, indicating a high potential for significant dilution for existing shareholders if fully utilized.

auto_awesomeAnalysis · MODD · Industrial Applications And Services

Modular Medical, Inc. has filed a new universal shelf registration statement, enabling it to raise up to $150 million through various securities, including a new $100 million At-The-Market (ATM) offering program. This move is critical for the company's survival, as it previously disclosed an immediate liquidity crisis and substantial doubt about its ability to continue as a going concern. While the recent FDA clearance for its Pivot insulin pump and regaining Nasdaq compliance are positive operational developments, the sheer scale of this potential capital raise, representing a significant multiple of its current market capitalization, indicates a desperate need for funds. The ATM program, in particular, allows for continuous share sales, which could exert sustained downward pressure on the stock price and result in substantial dilution for existing shareholders. This filing, while necessary to extend the company's operational runway, signals a challenging path ahead for equity investors.